Research ArticleOriginal Article
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
Runsen Jin, Chengming Liu, Sufei Zheng, Xinfeng Wang, Xiaoli Feng, Hecheng Li, Nan Sun and Jie He
Cancer Biology & Medicine August 2020, 17 (3) 768-781; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0121
Runsen Jin
1Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Chengming Liu
1Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Sufei Zheng
1Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Xinfeng Wang
1Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Xiaoli Feng
3Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Hecheng Li
2Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Nan Sun
1Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Jie He
1Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
References
- 1.↵
- 2.↵
- 3.↵
- Wakelee H,
- Belani CP.
- 4.↵
- Gainor JF,
- Shaw AT.
- 5.↵
- Lee CK,
- Man J,
- Lord S,
- Cooper W,
- Links M,
- Gebski V, et al.
- 6.↵
- Ribas A,
- Wolchok JD.
- 7.↵
- 8.↵
- 9.↵
- 10.
- 11.↵
- 12.↵
- Brustugun OT,
- Sprauten M,
- Helland A.
- 13.
- 14.↵
- Ahn BC,
- Pyo KH,
- Xin CF,
- Jung D,
- Shim HS,
- Lee CY, et al.
- 15.↵
- Yoneda K,
- Imanishi N,
- Ichiki Y,
- Tanaka F.
- 16.↵
- Gainor JF,
- Shaw AT,
- Sequist LV,
- Fu X,
- Azzoli CG,
- Piotrowska Z, et al.
- 17.↵
- Fehrenbacher L,
- Spira A,
- Ballinger M,
- Kowanetz M,
- Vansteenkiste J,
- Mazieres J, et al.
- 18.↵
- Schlam I,
- Dyehouse KM,
- Ward PJ.
- 19.↵
- 20.↵
- Dearden S,
- Stevens J,
- Wu YL,
- Blowers D.
- 21.↵
- 22.↵
- Osta BEE,
- Behera M,
- Kim S,
- Berry LD,
- Sica G,
- Pillai RN, et al.
- 23.↵
- Jordan EJ,
- Kim HR,
- Arcila ME,
- Barron D,
- Chakravarty D,
- Gao J, et al.
- 24.↵
- 25.↵
- Akbay EA,
- Koyama S,
- Carretero J,
- Altabef A,
- Tchaicha JH,
- Christensen CL, et al.
- 26.↵
- 27.↵
- Ribas A,
- Hu-Lieskovan S.
- 28.↵
- Teng MW,
- Ngiow SF,
- Ribas A,
- Smyth MJ.
- 29.↵
- Zhang Y,
- Ma Y,
- Li Y,
- Shen X,
- Yu Y,
- Pan Y, et al.
- 30.↵
- Rizvi H,
- Sanchez-Vega F,
- La K,
- Chatila W,
- Jonsson P,
- Halpenny D, et al.
- 31.↵
- 32.↵
- 33.↵
- Higgins JP,
- Altman DG,
- Gotzsche PC,
- Juni P,
- Moher D,
- Oxman AD, et al.
- 34.↵
- Dong ZY,
- Zhang JT,
- Liu SY,
- Su J,
- Zhang C,
- Xie Z, et al.
- 35.↵
- 36.↵
- Reck M,
- Mok TSK,
- Nishio M,
- Jotte RM,
- Cappuzzo F,
- Orlandi F, et al.
- 37.↵
- Seo JS,
- Ju YS,
- Lee WC,
- Shin JY,
- Lee JK,
- Bleazard T, et al.
- 38.↵
- Yang H,
- Shi J,
- Lin D,
- Li X,
- Zhao C,
- Wang Q, et al.
- 39.↵
- Su S,
- Dong ZY,
- Xie Z,
- Yan LX,
- Li YF,
- Su J, et al.
- 40.↵
- Hsu KH,
- Huang YH,
- Tseng JS,
- Chen KC,
- Ku WH,
- Su KY, et al.
- 41.↵
- 42.↵
- Ji M,
- Liu Y,
- Li Q,
- Li X,
- Ning Z,
- Zhao W, et al.
- 43.↵
- Toki MI,
- Mani N,
- Smithy JW,
- Liu Y,
- Altan M,
- Wasserman B, et al.
- 44.↵
- Ng TL,
- Liu Y,
- Dimou A,
- Patil T,
- Aisner DL,
- Dong Z, et al.
- 45.↵
- Wang GZ,
- Zhang L,
- Zhao XC,
- Gao SH,
- Qu LW,
- Yu H, et al.
- 46.↵
- 47.↵
- Zhang Y,
- Sheng J,
- Kang S,
- Fang W,
- Yan Y,
- Hu Z, et al.
- 48.↵
- Riely GJ,
- Pao W,
- Pham D,
- Li AR,
- Rizvi N,
- Venkatraman ES, et al.
In this issue
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
Runsen Jin, Chengming Liu, Sufei Zheng, Xinfeng Wang, Xiaoli Feng, Hecheng Li, Nan Sun, Jie He
Cancer Biology & Medicine Aug 2020, 17 (3) 768-781; DOI: 10.20892/j.issn.2095-3941.2020.0121
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
Runsen Jin, Chengming Liu, Sufei Zheng, Xinfeng Wang, Xiaoli Feng, Hecheng Li, Nan Sun, Jie He
Cancer Biology & Medicine Aug 2020, 17 (3) 768-781; DOI: 10.20892/j.issn.2095-3941.2020.0121
Jump to section
Related Articles
- No related articles found.